Wells Fargo’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $137K | Sell |
98,493
-187,272
| -66% | -$257K | ﹤0.01% | 4932 |
|
|
2025
Q4 | $460K | Buy |
285,765
+95,676
| +50% | +$200K | ﹤0.01% | 4554 |
|
|
2025
Q3 | $519K | Buy |
190,089
+30,498
| +19% | +$101K | ﹤0.01% | 4281 |
|
|
2025
Q2 | $581K | Buy |
159,591
+29,469
| +23% | +$81K | ﹤0.01% | 4030 |
|
|
2025
Q1 | $250K | Buy |
130,122
+7,725
| +6% | +$15.8K | ﹤0.01% | 4542 |
|
|
2024
Q4 | $233K | Buy |
122,397
+23,099
| +23% | +$40.1K | ﹤0.01% | 4702 |
|
|
2024
Q3 | $131K | Buy |
99,298
+3,199
| +3% | +$4.27K | ﹤0.01% | 4860 |
|
|
2024
Q2 | $98K | Buy |
96,099
+88,057
| +1,095% | +$109K | ﹤0.01% | 4951 |
|
|
2024
Q1 | $14.7K | Sell |
8,042
-3,054
| -28% | -$4.88K | ﹤0.01% | 5653 |
|
|
2023
Q4 | $13.8K | Buy |
11,096
+83
| +0.8% | +$85 | ﹤0.01% | 5740 |
|
|
2023
Q3 | $12.6K | Sell |
11,013
-118
| -1% | -$152 | ﹤0.01% | 5743 |
|
|
2023
Q2 | $10.2K | Sell |
11,131
-1,133
| -9% | -$1.09K | ﹤0.01% | 5897 |
|
|
2023
Q1 | $6.87K | Sell |
12,264
-1,215
| -9% | -$928 | ﹤0.01% | 5969 |
|
|
2022
Q4 | $7.78K | Sell |
13,479
-335
| -2% | -$105 | ﹤0.01% | 5642 |
|
|
2022
Q3 | $4K | Sell |
13,814
-1,142
| -8% | -$448 | ﹤0.01% | 5955 |
|
|
2022
Q2 | $4K | Sell |
14,956
-280,677
| -95% | -$118K | ﹤0.01% | 6061 |
|
|
2022
Q1 | $212K | Sell |
295,633
-52,320
| -15% | -$112K | ﹤0.01% | 4942 |
|
|
2021
Q4 | $787K | Buy |
347,953
+202,143
| +139% | +$551K | ﹤0.01% | 4310 |
|
|
2021
Q3 | $421K | Buy |
145,810
+126,159
| +642% | +$360K | ﹤0.01% | 4750 |
|
|
2021
Q2 | $75K | Sell |
19,651
-88,744
| -82% | -$299K | ﹤0.01% | 5402 |
|
|
2021
Q1 | $367K | Sell |
108,395
-152,311
| -58% | -$549K | ﹤0.01% | 4859 |
|
|
2020
Q4 | $730K | Sell |
260,706
-51,184
| -16% | -$149K | ﹤0.01% | 4250 |
|
|
2020
Q3 | $782K | Buy |
311,890
+5,567
| +2% | +$48.9K | ﹤0.01% | 4040 |
|
|
2020
Q2 | $4.16M | Buy |
306,323
+63,970
| +26% | +$662K | ﹤0.01% | 2639 |
|
|
2020
Q1 | $1.84M | Buy |
242,353
+40,510
| +20% | +$315K | ﹤0.01% | 3079 |
|
|
2019
Q4 | $1.28M | Sell |
201,843
-1,944
| -1% | -$9.24K | ﹤0.01% | 3695 |
|
|
2019
Q3 | $798K | Buy |
203,787
+34,392
| +20% | +$147K | ﹤0.01% | 4017 |
|
|
2019
Q2 | $820K | Buy |
169,395
+20,566
| +14% | +$117K | ﹤0.01% | 4026 |
|
|
2019
Q1 | $1.22M | Sell |
148,829
-9,781
| -6% | -$67.1K | ﹤0.01% | 3729 |
|
|
2018
Q4 | $878K | Buy |
158,610
+79,973
| +102% | +$626K | ﹤0.01% | 3933 |
|
|
2018
Q3 | $694K | Sell |
78,637
-41,048
| -34% | -$367K | ﹤0.01% | 4218 |
|
|
2018
Q2 | $1.19M | Buy |
119,685
+5,507
| +5% | +$55.1K | ﹤0.01% | 3870 |
|
|
2018
Q1 | $1.09M | Sell |
114,178
-7,034
| -6% | -$98.4K | ﹤0.01% | 3846 |
|
|
2017
Q4 | $1.8M | Buy |
121,212
+32,024
| +36% | +$531K | ﹤0.01% | 3447 |
|
|
2017
Q3 | $1.75M | Buy |
89,188
+1,072
| +1% | +$16.5K | ﹤0.01% | 3411 |
|
|
2017
Q2 | $1.27M | Buy |
88,116
+880
| +1% | +$11.2K | ﹤0.01% | 3551 |
|
|
2017
Q1 | $802K | Sell |
87,236
-1,811
| -2% | -$17.7K | ﹤0.01% | 3912 |
|
|
2016
Q4 | $926K | Buy |
89,047
+4,972
| +6% | +$42.8K | ﹤0.01% | 3762 |
|
|
2016
Q3 | $761K | Buy |
84,075
+952
| +1% | +$8.09K | ﹤0.01% | 3687 |
|
|
2016
Q2 | $621K | Sell |
83,123
-3,934
| -5% | -$34.3K | ﹤0.01% | 3782 |
|
|
2016
Q1 | $784K | Sell |
87,057
-5,094
| -6% | -$41.3K | ﹤0.01% | 3569 |
|
|
2015
Q4 | $1.19M | Buy |
92,151
+78,841
| +592% | +$804K | ﹤0.01% | 3369 |
|
|
2015
Q3 | $128K | Buy |
13,310
+5,189
| +64% | +$47.6K | ﹤0.01% | 4720 |
|
|
2015
Q2 | $84K | Buy |
8,121
+8
| +0.1% | +$68 | ﹤0.01% | 5154 |
|
|
2015
Q1 | $91K | Buy |
8,113
+1,150
| +17% | +$12.2K | ﹤0.01% | 4781 |
|
|
2014
Q4 | $80K | Buy |
6,963
+5,653
| +432% | +$81.1K | ﹤0.01% | 4830 |
|
|
2014
Q3 | $29K | Sell |
1,310
-2,147
| -62% | -$49.3K | ﹤0.01% | 5136 |
|
|
2014
Q2 | $96K | Buy |
+3,457
| New | +$83.2K | ﹤0.01% | 4700 |
|
Other funds holding AKBA
VCM
VPM
Wells Fargo's AKBA Position: Q1 2026 in Review
Wells Fargo reduced its Akebia Therapeutics (AKBA) stake by 66% in Q1 2026, selling an estimated $257K and leaving 98,493 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #4932.
Wells Fargo first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.16M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Wells Fargo held 98,493 shares of Akebia Therapeutics worth $137K as of Q1 2026.
- Wells Fargo sold 187,272 Akebia Therapeutics shares in Q1 2026, an estimated $257K.
- Akebia Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4932 holding.
- Wells Fargo first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
- Wells Fargo's Akebia Therapeutics position peaked at $4.16M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.